Compare Agilent Technologies Inc (A) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs iShares China Large-Cap ETF — how do they compare? Agilent Technologies Inc trades at $128.86 (market cap $37.04B), while iShares China Large-Cap ETF trades at $33.51. The key difference: Agilent Technologies Inc pays a 0.78% dividend while iShares China Large-Cap ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| A | FXI | |
|---|---|---|
Market Cap | $37.04B | — |
Sector | Health | — |
52-Week High | $157.20 | $41.75 |
52-Week Low | $110.24 | $31.59 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
The iShares China Large-Cap ETF (FXI) trades at $32.51, up 1.88% on the day, while technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. Recent news highlights China's AI and chip sector driving factory rebounds and IPO activity, though broader sentiment on Chinese equities remains mixed, with some analysts labeling them as potential value traps. The ETF shows neutral oscillator readings with key support at $32 and resistance at $33.
The outlook for FXI is clouded by structural macroeconomic headwinds in China, including deflationary pressures and geopolitical tensions with the U.S., which offset potential opportunities from the country's massive AI infrastructure investment plans. While the sector benefits from technology self-reliance initiatives, persistent risks to corporate profitability and valuation compression suggest a cautious approach for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
